Cozaar in heart failure

The licence for Cozaar (losartan) has been extended to include the treatment of chronic heart failure.

It is indicated in patients 60 years and over where treatment with ACE inhibitors is contraindicated or not tolerated, especially due to cough. Patients should have a left ventricular ejection fraction greater or equal to 40 per cent and be stabilised with chronic heart failure treatment. Patients with heart failure who have been stabilised with an ACE inhibitor should not be switched to losartan.

The starting dose is 12.5mg daily and can be titrated at weekly intervals to the usual maintenance dose of 50mg daily.

The MHRA have reinstated the black triangle on Cozaar, requesting that intensive monitoring is carried out for the use of Cozaar in heart failure.

View Cozaar drug record

Further information: Merck Sharp & Dohme

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...